Corrigendum to "Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study" [Heliyon 8 (6) (2022) e09538]
Heliyon. 2022 Nov 7;8(11):e11404.
doi: 10.1016/j.heliyon.2022.e11404.
eCollection 2022 Nov.
1 Medical school of Chinese PLA, Chinese PLA General Hospital, Beijing, 100853, China.
2 Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, 100039, China.
3 The Second Medical Center of PLA General Hospital, Beijing, 100039, China.